Secukinumab vs Ustekinumab in PsA Save
Dr. Antoni Chan reports on abstract LB06 (AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains), presented at the 2025 ACR Convergence meeting in Chicago
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.